Clinical cure rate in the worse eye (MFAS)
| Azithromycin (N=102) | Tobramycin (N=101) | Between-group* Difference | Superiority testing p value† | Non-inferiority testing‡ (95% CI) | |
|---|---|---|---|---|---|
| Day 3 | 48 (47.1%) | 29 (28.7%) | 18.3% | 0.013 | – (5.0 to 31.9) |
| Day 7 | 91 (89.2%) | 79 (78.2%) | 11.0% | 0.077 | Non-inferiority accepted (−2.9 to 24.3) |
*Azithromycin–tobramycin.
†Exact CMH test stratified by age group. Superiority was shown if p<0.05.
‡A non-inferiority margin of 10% was used (lower bound of the 95% CI ≥−10%). Non-inferiority testing was not performed on day 3.
CMH, Cochran–Mantel–Haenszel; MFAS, microbiologically positive full analysis set.